Difference between revisions of "Tranexamic acid"
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
Ostermayer (talk | contribs) (Text replacement - " DVT " to " DVT") |
||
| Line 11: | Line 11: | ||
*Greater than 3 hours from injury | *Greater than 3 hours from injury | ||
*Known sensitivity to TXA | *Known sensitivity to TXA | ||
| − | *Previous DVT or Pulmonary Embolism | + | *Previous [[DVT]]or Pulmonary Embolism |
==Administration== | ==Administration== | ||
Revision as of 20:33, 27 January 2017
Contents
Background
- Action: Antifibrinolytic agent
- Competitive inhibitor of plasminogen activation to plasmin
- Dosing Availability:
- Ampule of 1 Gm in 10 mL
Indication
Severely bleeding trauma patient, systolic blood pressure of <90 and/or heart rate > 110 beats/min., with expected requirement for massive transfusion.
Contraindication/Exclusion Criteria
- Greater than 3 hours from injury
- Known sensitivity to TXA
- Previous DVTor Pulmonary Embolism
Administration
Adult dose
Total of 2 Grams
- Initial bolus of 1 Gm over 10 minutes (Slow IV push). Draw up with filter needle.
- Maintenance: additional 1 Gm over next 8 hours (mix in 50 mL of NS). Call Pharmacy to mix and deliver the continuous infusion.[1]
Pediatric dose
Weight based
- Initial bolus of 20mg/kg IV Bolus over 10 minutes
- Maintenance: 10 mL/kg/hr over next 8 hours
No additional laboratory tests required.
Adverse Reactions
- Thrombotic events
- Hypotension with rapid injection
- Nausea, vomiting, diarrhea
- Impaired color vision and other visual disturbances
See Also
External Links
References
- ↑ CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011 Mar 26;377(9771):1096-101,